Top

Published in:

01-05-2010 | Original Article

Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series

Authors: Liliana Montella, Raffaele Addeo, Giovannella Palmieri, Michele Caraglia, Gregorio Cennamo, Bruno Vincenzi, Rosario Guarrasi, Rosanna Mamone, Vincenzo Faiola, Nicola Frega, Elena Capasso, Luigi Maiorino, Davide Leopardo, Carmine Pizza, Vincenzo Montesarchio, Salvatore Del Prete

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2010

Abstract

Purpose

The survival of patients with hepatocellular carcinoma (HCC) has improved with advancements in various diagnostic tools and treatment modalities. Consequently, bone metastases from HCC are diagnosed more frequently. The aims of the present study was to describe the clinical features and treatment of HCC patients presenting with bone metastases. In particular, we evaluated the role of zoledronic acid in these patients especially with regard to pain reduction, analgesic drug consumption and safety.

Methods

Between December 2006 and July 2008, we recruited 17 (male:female, 12:5, median age, 68 years; age range, 62–85 years) consecutive patients. Spinal metastases were present in 11 patients (64.7%). Zoledronic acid was administered in all patients (total number of administrations, 107; mean number of administrations, 6.29).

Results

A total of 15 patients received at least three administrations of zoledronic acid and reported clinical benefit with pain reduction and tapering of analgesic drugs. Before starting treatment, the mean VAS for patients who received at least three administrations (15/17 patients) of zoledronic acid was 7.1 (±0.24), and after 3 months 5.3 (±0.20). This improvement was independent of the sex, the extent of metastasis and the concomitant anticancer treatment. No significant side effects were registered in this series of patients. Median survival was 10 months (CI 6,353–13,647).

Conclusions

Zoledronic acid may be helpful in treating bone metastases in HCC patients. Patients regularly receiving zoledronic acid showed significant pain relief.

Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol S20–S37

Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A, Del Prete S (2008) Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. Oncol Rep 20:385–390PubMed

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma N Engl J Med 24;359:378–90

Katyal S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL (2000) Extrahepatic metastases of hepatocellular carcinoma. Radiology 216:698–703PubMed

Attili VS, Babu KG, Lokanatha D, Bapsy PP, Ramachandra C, Rajshekar H (2008) Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment. J Cancer Res Ther 4:93–94CrossRefPubMed

Doval DC, Bhatia K, Vaid AK, Pavithran K, Sharma JB, Hazarita D, Jena A (2006) Spinal cord compression secondary to bone metastases from hepatocellular carcinoma. World J Gastroenterol 12:5247–5252PubMed

Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, Wakasugi H, Iguchi H (2001) Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 13:1083–1088CrossRefPubMed

Berenson JR (2005) Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10:52–62CrossRefPubMed

Okusaka T, Okada S, Ishii H, Nose H, Nagahama H, Nakasuka H, Ikeda K, Yoshimori M (1997) Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 44:251–257PubMed

10.

Janjan NA (1997) Radiation for bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer 80:1628–1645CrossRefPubMed

11.

Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432CrossRefPubMed

12.

Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S, Vijayakumar V (2007) The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 99:785–794PubMed

13.

Kruskal, Wallis (1952) Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47:583–621CrossRef

14.

Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

15.

Borghetti M, Benelli G, Bonardi R, Reduzzi L, Iori M (1991) Bone metastasis of hepatocarcinoma. Review of the literature, radiologic pictures and personal caseload. Radiol Med (Torino) 82(4):8–51

16.

Kuhlman JE, Fishman EK, Leichner PK, Magid D, Order SE, Siegelman SS (1986) Skeletal metastases from hepatoma: frequency, distribution, and radiographic features. Radiology 160:175–178PubMed

17.

Sueyoshi K, Narabayashi I, Doi K, Takahashi M, Komori T, Tatsu Y, Tatsumi T, Utunomiya K, Uesugi Y, Adachi I, Shimizu T (2000) Tc-99m PMT whole-body scintigraphy for evaluated of therapeutic effect and for monitoring bone metastasis in a patient with hepatocellular carcinoma. Clin Nucl Med 25:1000–1003CrossRefPubMed

18.

Groves AM, Beadsmoore CJ, Cheow HK, Balan KK, Courtney HM, Kaptoge S, Win T, Harish S, Bearcroft PW, Dixon AK (2006) Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient. Eur Radiol 16:1066–1073CrossRefPubMed

19.

Barni S, Mandalà M, Cazzaniga M, Cabiddu M, Cremonesi M (2006) Bisphosphonates and metastatic bone disease. Ann Oncol 17((Suppl2)):ii91–ii95CrossRefPubMed

20.

Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A (2006) Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13:7–26CrossRefPubMed

21.

Arrington SA, Damron TA, Mann KA, Allen MJ (2008) Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis. J Surg Oncol 97:284–290CrossRefPubMed

22.

Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624CrossRefPubMed

23.

Crawford BAL, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW (2006) Zoledronic acid prevents bone loss after liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 144:239–248PubMed

24.

Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, Wiese M, Moessner J (2005) Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 11:1843–1847PubMed

25.

Ohnishi T, Takeda E, Yogita S, Miyake H, Kinoshita T, Terashima Y, Matsumoto T, Tashiro S (2000) Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. Jpn J Clin Oncol 30:410–413CrossRefPubMed

26.

Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini D, Caraglia M, Del Prete S (2008) Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Support Care Cancer 16:209–214CrossRefPubMed

27.

Montella L, Merola C, Merola G, Petillo L, Palmieri G (2009) Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab 27:110–113CrossRefPubMed

28.

Montella L, Addeo R, Faiola V, Cennamo G, Guarrasi R, Capasso E, Mamone R, Caraglia M, Del Prete S (2009) Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. J Exp Clin Cancer Res 28:7CrossRefPubMed

Title: Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series
Authors: Liliana Montella
Raffaele Addeo
Giovannella Palmieri
Michele Caraglia
Gregorio Cennamo
Bruno Vincenzi
Rosario Guarrasi
Rosanna Mamone
Vincenzo Faiola
Nicola Frega
Elena Capasso
Luigi Maiorino
Davide Leopardo
Carmine Pizza
Vincenzo Montesarchio
Salvatore Del Prete
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1122-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2010

Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients

Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children

PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer

Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer